bioRxiv · 10.64898/2026.04.02.715976
Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Abstract
Chimeric antigen receptor (CAR) T cells have transformed cancer treatment, yet challenges for achieving broader clinical success remain, including overcoming tumor antigen heterogeneity and limited T cell fitness. To address these challenges and enhance CAR T cell functionality, we leveraged meditope technology, a lock-and-key platform where Fab regions of antibodies are modified to bind a small cyclic peptide termed meditope (meP). We developed a panel of meditope-enabled Fab-based CARs (meCARs), which show selective binding to the meP and comparable activity to traditional single-chain variable fragment (scFv)-based CARs. Focusing on HER2-targeted meCARs for evaluating platform utility, we exploited the modularity of the meditope platform to detect meCAR T cells using meP-fused fluorescent agents, promote meCAR T cell expansion via meP-fused IL-15 cytokine, and broaden tumor antigen targeting through meP-fused antibodies to address tumor heterogeneity. These findings establish the meditope technology as a versatile strategy to augment CAR T cell functionality and overcome key limitations of current CAR-based therapies.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Kuo, C.-F., Tong, Z., Kuo, Y.-C., Kuo, M., King, J., Ly, K., Parcutela, B., Stern, L. A., Wang, Z., Aguilar, B., Starr, R., Chang, W.-C., Ostberg, J. R., Rossi, D., Clark, M. C., Alizadeh, D., Forman, S. J., Williams, J. C., Brown, C. E.. 2026-04-06. Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells. https://doi.org/10.64898/2026.04.02.715976
Cite the original work for its findings. Save a collection to share your selection of sources.